Entity

Time filter

Source Type


Tasci C.,Gulhane Medical Faculty | Ozkaya S.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery | Ozkara B.,Military Hospital | Tozkoparan E.,Gulhane Medical Faculty | And 5 more authors.
OncoTargets and Therapy | Year: 2012

Aim: Both of the diagnosis and treatment evaluation are time-consuming conditions in patients with pulmonary and pleural tuberculosis. The aim of this study was to establish the validity of tumor markers CA 125, CA 15-3, and CA 19-9 in the diagnosis of pulmonary and pleural TB and to verify the success of the treatment protocol. Patients and methods: The levels of tumor markers CA 125, CA 15-3, and CA 19-9 were measured before and after treatment in 67 TB patients, 54 of whom had pulmonary TB and 13 of whom had pleural TB. All values were compared with the results of a healthy control group of 44 subjects. Results: CA 125 and CA 15-3 levels were significantly high when compared with those of the healthy control group and there was a significant decrease in both tumor marker levels after treatment in patients with pulmonary TB (P< 0.001 and P< 0.004, respectively). However, the difference found in CA 19-9 levels before and after treatment in patients with pulmonary TB was not statistically significant (P< 0.08). When the CA 125, CA 15-3, and CA 19-9 values of the pulmonary TB group before treatment were compared with that of the healthy control group, the results were statistically significant in all parameters except CA 19-9 (P< 0.001, P< 0.001, and P< 0.09 for CA 125, CA 15-3, and CA 19-9, respectively). In the patients with pleural TB, CA 125, CA 15-3, and CA 19-9 values did not change significantly after treatment. Conclusion: The authors suggest that CA 125 and CA 15-3 tumor markers may be important for verification of the success of treatment protocol in pulmonary TB, as the differences found for these tumor markers between the pre- and the post treatment periods are statistically significant. © 2012 Tasci{dotless} et al, publisher and licensee Dove Medical Press Ltd. Source


Ozkaya S.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery
Therapeutics and Clinical Risk Management | Year: 2012

Background: The results of sputum culture for Mycobacterium tuberculosis must be awaited in most cases, which delays the start of treatment in patients with sputum smear-negative pulmonary tuberculosis. We investigated whether plasma chitotriosidase activity is a strong marker for early diagnosis of tuberculosis in patients for whom a bacillus smear is negative and tuberculosis culture is positive. Methods: Clinical, radiological, and laboratory features were evaluated in 75 patients, 17 of whom were diagnosed as having active tuberculosis by negative acid-fast bacillus smear and positive culture, 38 as having sequel tuberculosis which was radiologically and microbiologically negative, and 20 who served as healthy controls. Serum chitotriosidase activity levels were measured in both cases and controls. Results: The mean age of the cases with active pulmonary tuberculosis, cases with sequel lesions, and controls was 23 ± 2.4 years, 22 ± 1.7 years, and 24 ± 2.1 years, respectively. Serum chitotriosidase levels were 68.05 ± 72.61 nmol/hour/mL in smear-negative, culture-positive pulmonary tuberculosis cases (Group A) and 29.73 ± 20.55 nmol/hour/mL in smear-negative, culture-negative sequel pulmonary tuberculosis cases (Group B). Serum chitotriosidase levels from patients in Group A were significantly higher than in Group B and Group C. There was no statistically significant difference in serum chitotriosidase levels between cases with sequel pulmonary tuberculosis (Group B, smear-negative, culture-negative) and healthy controls (Group C). Conclusion: In patients with active tuberculosis and a negative sputum smear for acid-fast bacillus, plasma chitotriosidase activity seems to be a strong marker for diagnosis of active disease which can be used while awaiting culture results. © 2012 Tasci et al, publisher and licensee Dove Medical Press Ltd. Source


Musellim B.,Istanbul University | Okumus G.,Istanbul University | Uzaslan E.,Uludag University | Akgun M.,Ataturk University | And 51 more authors.
Clinical Respiratory Journal | Year: 2014

Introduction: There is very few data on the epidemiological features of interstitial lung diseases (ILD) in the literature. These studies on this subject suffer from limited number of patients. Objective: The goal of this study was to evaluate the epidemiological features of ILD in Turkey. Methods: Fifty-four investigators, 31 centres in 19 cities from six regions of Turkey, participated in the study. Two thousand two hundred forty-five newly diagnosed patients (51.8% females), led by Turkish Thoracic Society Clinical Problems Study Group, enrolled in this prospective study. Results: The mean age was 51.8±16.7 years. The mean age among males was 50.5±18.6 years and 53.0±14.6 years among females (P<0.001). 23.8% of the cases had ILD with known causes, while 39.4% were in granulomatous group, 23.7% were idiopathic, and 4.4% were in the unclassified group. Overall, histopathologically confirmed diagnosis rate was 40.4%. Sarcoidosis was the most common disease (37%), whereas cases with idiopathic pulmonary fibrosis (IPF) constituted 19,9% of patients. 53% of the sarcoidosis patients were females, and the ratio reaches to 75% under 50 years of age (for this group, IPF ratio is %3). In contrast, sarcoidosis and IPF ratios were equal in males (25%). Sarcoidosis was 8% in men over 50, while IPF was %45. Conclusion: The overall incidence of ILD in Turkey was computed to be 25.8/100000. © 2013 John Wiley & Sons Ltd. Source


Komurcuoglu B.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery | Ozkaya S.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery | Cirak A.K.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery | Yalniz E.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery | Polat G.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery
Experimental Lung Research | Year: 2012

Background and objectives: Pulmonary hydatid cyst (PHC) is a parasitic infestation caused by larvae of Echinococcus granulosus. The lung is the most commonly involved organ after the liver. There is lack of enough data on the efficacy of bronchoscopy in patients with PHC, and the diagnostic usefulness of bronchoscopy is still controversial. We aimed to present the diagnostic efficacy of bronchoscopy and disease characteristics of patients with PHC. Methods: PHC was diagnosed in 72 patients51 of patients in Group I (uncomplicated PHC) and 49 of patients in Group II (complicated PHC)in Dr Suat Seren Education and Research Hospital for Chest Diseases and Thoracic Surgery. The data of patients including age, gender, symptoms, and radiological, bronchoscopic, microbiological, and pathological findings were retrospectively evaluated. Results: The bronhoscopic findings were defined as hyperemia (44), normal (38), edema (32), purulent secretion (24), external bronchial compression (24), and endobronchial cyst membrane (21), respectively. Cyst membranes were seen during bronchoscopy in 7 (20.5) of the patients and 6 (86) of them were in Group II. Hydatoptosis (expectoration of cyst contents), cough, hemoptysis, leukocytosis, Echinecoccus IgG positivity, chest pain, and fever were significantly higher in Group II. According to radiological images, the multiple cystic nodular lesions and well-shaped cystic nodular lesions were significantly higher in Group I. However, water-lily sign, images of abscess, and pneumonic infiltration were significantly higher in Group II. Conclusion: The diagnosis of PHC is usually made with the combination of clinical, radiological, serological, and surgical procedures. We suggest that the fiberoptic bronchoscopy can be used as a diagnostic method, especially in complicated PHC. © Informa Healthcare USA, Inc. Source


Tekgul S.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery | Bilaceroglu S.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery | Ozkaya S.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery | Coskun A.,Dr Suat Seren Education And Research Hospital For Chest Diseases And Thoracic Surgery | And 2 more authors.
Respiratory Medicine Case Reports | Year: 2012

Pulmonary alveolar proteinosis (PAP) is a rare and diffuse lung process, characterized by the presence of alveolar spaces filled with amorphous eosinophilic material. Impaired macrophage function and impaired host defence due to abnormalities of surfactant proteins may favor the growth of microorganisms. The association of alveolar proteinosis with mycobacterial infections is rarely reported. The PAP and superinfection with pulmonary tuberculosis is defined by radiologic and histopathologic in a 46 year-old patient. The patients with PAP should be monitored for superinfection. It may cause the disease progression and radiological, clinical symptoms may improve with treatment of superinfection. © 2011. Source

Discover hidden collaborations